BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 18028436)

  • 21. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
    Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different circulating metalloproteinases profiles in women with migraine with and without aura.
    Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
    Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma.
    Pennanen H; Kuittinen O; Soini Y; Turpeenniemi-Hujanen T
    Eur J Haematol; 2008 Oct; 81(4):289-97. PubMed ID: 18616513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
    Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
    Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MMP and TIMP alterations in asymptomatic and symptomatic severe recurrent carotid artery stenosis.
    Sapienza P; Borrelli V; di Marzo L; Cavallaro A
    Eur J Vasc Endovasc Surg; 2009 May; 37(5):525-30. PubMed ID: 19297218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
    Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
    Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinases (MMP-8, MMP-9) and the tissue inhibitors of metalloproteinases (TIMP-1, TIMP-2) in patients with fungal keratitis.
    Rohini G; Murugeswari P; Prajna NV; Lalitha P; Muthukkaruppan V
    Cornea; 2007 Feb; 26(2):207-11. PubMed ID: 17251814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
    Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
    Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metalloproteinase expression in carotid plaque and its correlation with plasma levels before and after carotid endarterectomy.
    Taurino M; Raffa S; Mastroddi M; Visco V; Rizzo L; Torrisi MR; Faraglia V
    Vasc Endovascular Surg; 2007 Dec-2008 Jan; 41(6):516-21. PubMed ID: 18166633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
    Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
    J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
    Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
    Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
    Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
    Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients.
    Iizasa T; Fujisawa T; Suzuki M; Motohashi S; Yasufuku K; Yasukawa T; Baba M; Shiba M
    Clin Cancer Res; 1999 Jan; 5(1):149-53. PubMed ID: 9918213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
    Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
    J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
    Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
    Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
    Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
    Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
    Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
    Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM; Gunasinghe HR; Coker ML; Sprunger P; Lee-Jackson D; Bozkurt B; Deswal A; Mann DL; Spinale FG
    J Card Fail; 2002 Dec; 8(6):390-8. PubMed ID: 12528092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.